Advertisement
Advertisement
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
4.00
USDSponsored
+0.03
+0.88%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
4.01
+0.01
+0.37%
OKUR Earnings Reports
Positive Surprise Ratio
OKUR beat 12 of 20 last estimates.
60%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.87
Implied change from Q4 25 (Revenue/ EPS)
--
/-12.12%
Implied change from Q1 25 (Revenue/ EPS)
--
/-26.89%
OnKure Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On Mar 12, 2026, OKUR reported earnings of -0.99 USD per share (EPS) for Q4 25, beating the estimate of -1.17 USD, resulting in a 15.74% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.39% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.87 USD, with revenue projected to reach -- USD, implying an decrease of -12.12% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were OnKure Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, OnKure Therapeutics, Inc. Class A Common Stock reported EPS of -$0.99, beating estimates by 15.74%, and revenue of $0.00, 0% as expectations.
How did the market react to OnKure Therapeutics, Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved up 7.39%, changed from $3.52 before the earnings release to $3.78 the day after.
When is OnKure Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for OnKure Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 3
analysts, OnKure Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.87 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement